# Lunai Bioworks Inc. (LNAI)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Price:** $2.52 (+11.50%)

> Lunai Bioworks Inc. is a pre-clinical stage biotechnology company that develops medicine, diagnostics, and biodefense products. The company integrates artificial intelligence, genomics, and living biological systems to decode disease mechanisms and identify therapeutic targets. Its pipeline includes genetically modified dendritic cell therapeutic vaccines, such as RENB-DC11 for pancreatic cancer and RENB-DC20 for breast cancer treatment. Lunai Bioworks operates through multiple segments, including RENB, BioSymetrics, and RENC. The company employs proprietary AI platforms combined with zebrafish models to uncover drug efficacy, safety profiles, and clinical biomarkers that traditional research methods may overlook. By integrating phenotypic, proteomic, and genomic data, Lunai Bioworks aims to create clear pathways from disease discovery to patient benefit, focusing on precision medicine approaches for oncology and other therapeutic areas. Headquartered in Los Angeles, California, the company serves both the United States and Netherlands markets.

Financial data not yet available for this company.

Source: [CompaniesByCap](https://companiesbycap.com/company/LNAI)